DURECT Corp. (DRRX)

0.73
NASDAQ : Health Technology
Prev Close 0.67
Day Low/High 0.69 / 0.73
52 Wk Low/High 0.46 / 1.66
Avg Volume 936.30K
Exchange NASDAQ
Shares Outstanding 191.36M
Market Cap 128.96M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

DURECT Receives Approval From Nasdaq For Transfer Of Listing To Nasdaq Capital Market

DURECT Receives Approval From Nasdaq For Transfer Of Listing To Nasdaq Capital Market

CUPERTINO, Calif., June 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's common...

DURECT Announces $15 Million Registered Direct Offering

DURECT Announces $15 Million Registered Direct Offering

CUPERTINO, Calif., June 20, 2019 /PRNewswire/ -- DURECT Corporation ("DURECT" or the "Company") (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and...

DURECT Announces Completion Of The 90 Mg Severe Cohort And Dose Escalation Committee Approval To Commence 150 Mg Dosing In Patients With Severe Alcoholic Hepatitis (AH) In Its Ongoing DUR-928 Phase 2a AH Trial

DURECT Announces Completion Of The 90 Mg Severe Cohort And Dose Escalation Committee Approval To Commence 150 Mg Dosing In Patients With Severe Alcoholic Hepatitis (AH) In Its Ongoing DUR-928 Phase 2a AH Trial

CUPERTINO, Calif., June 18, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and...

DURECT To Present At The 20th Annual B. Riley FBR Institutional Investor Conference On May 22, 2019

DURECT To Present At The 20th Annual B. Riley FBR Institutional Investor Conference On May 22, 2019

CUPERTINO, Calif., May 16, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E.

DURECT Corporation Announces Preliminary Data From The Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

DURECT Corporation Announces Preliminary Data From The Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

Live Webcast of AH Data Presentation and Discussions by KOLs Steven Flamm, M.D., Tarek I. Hassanein, M.D. and Paul Kwo, M.D. Tomorrow, Wednesday, May 8, 2019 at 8:30 a.m. ET

DURECT Corporation Announces First Quarter 2019 Financial Results And Update Of Programs

DURECT Corporation Announces First Quarter 2019 Financial Results And Update Of Programs

Live Webcast of Alcoholic Hepatitis KOL and Earnings Call on Wednesday, May 8th at 8:30 a.m. ET

DURECT Corporation To Present Preliminary Data From The Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial And Report First Quarter 2019 Financial Results

DURECT Corporation To Present Preliminary Data From The Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial And Report First Quarter 2019 Financial Results

Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D.

DURECT Appoints Two New Board Members

DURECT Appoints Two New Board Members

CUPERTINO, Calif., April 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of two new members to its board of directors.

DURECT To Present At The H.C. Wainwright Global Life Sciences Conference And Host An Upcoming KOL Call On NASH

DURECT To Present At The H.C. Wainwright Global Life Sciences Conference And Host An Upcoming KOL Call On NASH

CUPERTINO, Calif., April 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg, Chief Financial Officer, will be presenting at the H.

DURECT Announces Patient Enrollment In Phase 1b Clinical Trial Of Oral DUR-928 In Patients With Non-Alcoholic Steatohepatitis (NASH)

DURECT Announces Patient Enrollment In Phase 1b Clinical Trial Of Oral DUR-928 In Patients With Non-Alcoholic Steatohepatitis (NASH)

CUPERTINO, Calif., March 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH.

DURECT Announces Patient Dosing In Phase 2a Proof-of-Concept Clinical Trial Of Topical DUR-928 In Patients With Mild To Moderate Plaque Psoriasis

DURECT Announces Patient Dosing In Phase 2a Proof-of-Concept Clinical Trial Of Topical DUR-928 In Patients With Mild To Moderate Plaque Psoriasis

CUPERTINO, Calif., March 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis.

DURECT Corporation Announces Fourth Quarter And Full Year 2018 Financial Results And Update Of Programs

DURECT Corporation Announces Fourth Quarter And Full Year 2018 Financial Results And Update Of Programs

Advancing To Next Dosing Cohort in Severe Alcoholic Hepatitis (AH) Patients

DURECT Corporation Invites You To Join Its Fourth Quarter 2018 Earnings Conference Call

DURECT Corporation Invites You To Join Its Fourth Quarter 2018 Earnings Conference Call

CUPERTINO, Calif., March 4, 2019 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on...

DURECT Announces Plans To Submit To FDA A Full Response To The POSIMIR® Complete Response Letter

DURECT Announces Plans To Submit To FDA A Full Response To The POSIMIR® Complete Response Letter

Live Webcast Today at 10:30 a.m. Eastern Time

DURECT Corporation To Participate In The Berenberg NASH Day

DURECT Corporation To Participate In The Berenberg NASH Day

CUPERTINO, Calif., Feb.

First Week Of DRRX August 17th Options Trading

First Week Of DRRX August 17th Options Trading

Investors in Durect Corp saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRRX options chain for the new August 17th contracts and identified the following call contract of particular interest.

Short Interest Jumps 20.4% For DRRX

Short Interest Jumps 20.4% For DRRX

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 341,730 share increase in total short interest for Durect Corp , to 2,014,989, an increase of 20.42% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting DRRX Call Options For January 2018

Investors in Durect Corp saw new options become available this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Durect Stock Sees Short Interest Fall 19.6%

Durect Stock Sees Short Interest Fall 19.6%

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 686,881 share decrease in total short interest for Durect Corp , to 2,816,491, a decrease of 19.61% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest In Durect Moves 21.5% Higher

Short Interest In Durect Moves 21.5% Higher

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 743,073 share increase in total short interest for Durect Corp , to 4,195,826, an increase of 21.52% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies are scooping up shares of their own stock lately.

Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection

Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection

Durect Corp.'s (DRRX) licensee Pain Therapeutics (PTIE) new drug application for an opioid analgesic was denied by the FDA.

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

Here's a technical look at how to trade some of the most active stocks on the market right now.

Interesting DRRX Call Options For April 2017

Interesting DRRX Call Options For April 2017

Investors in Durect Corp saw new options begin trading today, for the April 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Insider Trading Alert - SMLP, DRRX And MDSO Traded By Insiders

Insider Trading Alert - SMLP, DRRX And MDSO Traded By Insiders

Stocks with insider trader activity include SMLP, DRRX and MDSO

Insider Trading Alert - DRRX, EA and KAI Traded By Insiders

Insider Trading Alert - DRRX, EA and KAI Traded By Insiders

Stocks with insider trader activity include DRRX, EA and KAI

Durect Stock Sees Short Interest Make 130.4% Move

Durect Stock Sees Short Interest Make 130.4% Move

The most recent short interest data has been released by the NASDAQ for the 07/15/2015 settlement date, which shows a 3,326,063 share increase in total short interest for Durect Corp , to 5,876,167, an increase of 130.43% since 06/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of DRRX August 21st Options Trading

First Week of DRRX August 21st Options Trading

Investors in Durect Corp saw new options begin trading this week, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRRX options chain for the new August 21st contracts and identified the following call contract of particular interest.

TheStreet Quant Rating: D- (Sell)